Search results
COVID shots should target JN.1 variant in 2024-25 campaign, US FDA says
Reuters· 19 minutes agoThe U.S. Food and Drug Administration on Friday advised COVID-19 vaccine manufacturers that new shots for the fall 2024 campaign should target the JN.1 variant that was dominant earlier this year.
What should you do if you’re still testing positive for COVID-19 after day 10?
The Today Show via AOL· 3 days agoWith new coronavirus strains popping up, experts are concerned about a possible COVID-19 spike this...
COVID-19 Virus Can Lurk in Sperm for 100+ Days After Infection
SciTechDaily· 3 hours agoSARS-CoV-2 was detected in male reproductive cells under the microscope even when PCR testing failed...
Early June seeing uptick in summer colds, viruses, COVID-19 cases on Long Island, doctors say
Newsday· 1 day agoWhile some of the viruses being seen tend to be more prevalent as summer approaches, possible...
FDA vaccine advisers vote unanimously in favor of updated Covid-19 shot for fall
CNN.com· 2 days agoThe US Food and Drug Administration’s committee of independent advisers voted unanimously Wednesday...
The disproportionate toll that COVID-19 took on people with diabetes continues today
Medical Xpress· 23 hours agoAt the start of the pandemic, many people living with diabetes were wondering what COVID-19 meant...
Biden gets a boost ahead of Trump debate as economy outperforms expectations
The Independent via Yahoo News· 5 minutes agoPolling has consistently shown that voters trust the former president with the economy more than the...
Moderna Files FDA Application for the JN.1 Targeting COVID-19 Vaccine
The Kansas City Star· 1 hour agoManufacturing is underway and doses of Moderna’s Spikevax 2024-2025 formula will be ready to ship as early as August, pending regulatory approval
Here's Why Thermo Fisher (TMO) Should be in Your Portfolio
Zacks via Yahoo Finance· 2 hours agoTMO is gaining investors’ confidence due to its impressive partnerships. Of late, the company has...
Stock Split Watch: 3 Growth Stocks That Could Be Next
Motley Fool via Yahoo Finance· 1 hour agoIn the first quarter, Regeneron's revenue decreased by 1% year over year to $3.15 billion due to a...